Oral News and Research

RSS

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naive HCV patients. ANA598 is an investigational, oral, non-nucleoside polymerase inhibitor.

9 Sep 2009

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”) (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that the National Institutes of Health (“NIH”) has awarded a $2.87 million grant to fund the pre clinical development of a Ceragenin™based oral drug to treat two common and potentially deadly gastrointestinal infections: Clostrdium difficile and Shigella.

9 Sep 2009

INSPIRE Phase I/IIa study data to be presented at ICAAC

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that data from an interim analysis of its INSPIRE Phase I/IIa study of HIV-infected patients with low CD4 T cell counts treated with a three injection cycle of the Company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), will be presented during an oral late breaker session at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held September 12-15, 2009, in San Francisco, CA.

9 Sep 2009

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

The first results of the first European survey of cancer patients' experience of breakthrough pain were presented today at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC).

9 Sep 2009

Amarillo Biosciences is midway in Phase 2 clinical study of interferon against H1N1

Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that a Phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study in Perth, Australia achieved full target enrollment of 200 subjects and 98% of the subjects remain on study drug. Subjects in the study are receiving a lozenge containing interferon-alpha or a matching placebo once a day for 16 weeks.

9 Sep 2009

Meda launches EDLUAR in the U.S.

Meda Pharmaceuticals Inc. (Meda) today announced the commercial availability of EDLUAR(TM) (zolpidem tartrate sublingual tablets) in the United States. EDLUAR is indicated for the short-term treatment of insomnia characterized by difficulties with falling asleep. EDLUAR is the first available under-the-tongue formulation of zolpidem tartrate, which is the most prescribed treatment for insomnia. Zolpidem tartrate is also the active ingredient in Ambien(R) oral tablets.

9 Sep 2009

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries Ltd. today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009.

9 Sep 2009

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza.

9 Sep 2009

Doctors view on surrogate decision making process

A growing number of hospitalized adults are incapable of making their own health decisions, but little research has explored how doctors feel about making medical decisions with a patient's surrogate decision maker.

9 Sep 2009

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

The makers of Aquafresh(R) and Sensodyne(R) introduce a breakthrough technology in toothpaste - new iso-active(R) Foaming Gel. Iso-active has a revolutionary delivery system that disperses active ingredients quickly, penetrating those hard-to-reach areas of the mouth.

8 Sep 2009

Western Dental Services launches digital X-ray imaging program

CDW Healthcare, part of the public sector subsidiary of CDW Corporation and a leading provider of technology products and services to healthcare organizations, today announced that Western Dental Services, Inc. (“Western Dental”) of Orange, Calif., launched an extensive digital X-ray imaging program powered via technology configured and deployed by CDW Healthcare.

8 Sep 2009

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis.

8 Sep 2009

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Chronic periodontitis linked to head and neck cancer

Chronic periodontitis, a form of gum disease, is an independent risk factor for head and neck squamous cell carcinoma. This suggests the need for increased efforts to prevent and treat periodontitis as a possible means to reduce the risk of this form of cancer.

8 Sep 2009

Renewal of CytoCare and i.v.STATION distribution agreements

Health Robotics today announced that after a successful first year of cooperation in Japan with Tosho Inc., the companies signed this week a contract renewal of the CytoCare and i.v.STATION exclusive distribution agreements, and an expansion of their strategic relationship to include future joint-development projects in their respective areas of Pharmacy Automation expertise.

7 Sep 2009

Health care reform could affect Americans having dental and vision coverage policies

Over 132 million Americans face having their family dental and vision coverage split in two under current Congressional proposals for health care reform, according to the National Association of Dental Plans whose members cover 80 percent of Americans with dental benefits.

5 Sep 2009

Solution for fecal incontinence in children

Encopresis isn't the sort of medical problem making headlines, but there's no mistaking the quiet emotional toll it takes on children as school resumes across the country. Bright, vivacious boys and girls in elementary school are becoming quiet, withdrawn and ostracized. After all, children can be cruel and nobody wants to associate with the "smelly kid" sitting all alone.

4 Sep 2009

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today the initiation of two clinical trials with OSI-906, the Company’s potential first-in-class, oral insulin-like growth factor-1 receptor (IGF-1R) inhibitor. The first study is a Phase III, multi-center study that will evaluate the use of OSI-906 for patients with locally advanced or metastatic adrenocortical carcinoma (ACC).

4 Sep 2009

IND for Cytopia's CYT387 clears the FDA review

Cytopia Limited's Investigational New Drug Application (IND) for CYT387 has passed US Food and Drug Administration (FDA) review. CYT387 is a small-molecule oral JAK1/JAK2 kinase inhibitor designed to treat various haematological disorders.

4 Sep 2009

Dentists recommend healthy foods for children’s oral hygiene

You wouldn’t send your children to school with a lunchbox full of candy bars, but you might be packing almost as much sugar when you send them off with some popular lunchtime classics. Considering most children brush their teeth in the morning and before bed, the sugar they put in their mouths at lunchtime could stay there for a while, and that worries some dentists.

4 Sep 2009

Oral News and Research

Phase II trial of ANA598 commenced by Anadys Pharmaceuticals

Ceragenix awarded $2.87M NIH grant to develop a drug for treating Clostrdium difficile and Shigella

INSPIRE Phase I/IIa study data to be presented at ICAAC

First results of European survey of cancer patients' experience of breakthrough pain presented at EFIC

Amarillo Biosciences is midway in Phase 2 clinical study of interferon against H1N1

Meda launches EDLUAR in the U.S.

Teva Pharmaceutical Industries to present MS treatment research data

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

Doctors view on surrogate decision making process

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

Western Dental Services launches digital X-ray imaging program

DOR's Phase 1/2 clinical trial for prevention of radiation enteritis receives NIH grant

Third human clinical trial of LigoCyte's norovirus vaccine started

Chronic periodontitis linked to head and neck cancer

Renewal of CytoCare and i.v.STATION distribution agreements

Health care reform could affect Americans having dental and vision coverage policies

Solution for fecal incontinence in children

OSI Pharmaceuticals initiates two clinical trials with OSI-906 oral insulin-like growth factor-1 receptor inhibitor

IND for Cytopia's CYT387 clears the FDA review

Dentists recommend healthy foods for children’s oral hygiene

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News